Charles River Laboratories International (NYSE:CRL) Releases FY21 Earnings Guidance

Charles River Laboratories International (NYSE:CRL) issued an update on its FY21 earnings guidance on Tuesday morning. The company provided EPS guidance of $9.75-$10.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $9.21. Charles River Laboratories International also updated its FY 2021 guidance to 9.750-10.000 EPS.

Shares of CRL traded up $7.01 during mid-day trading on Tuesday, reaching $338.96. 652,947 shares of the company’s stock traded hands, compared to its average volume of 321,532. The business’s 50-day moving average price is $307.12 and its 200-day moving average price is $269.37. The stock has a market capitalization of $17.02 billion, a P/E ratio of 56.49, a price-to-earnings-growth ratio of 2.19 and a beta of 1.12. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.22 and a current ratio of 1.45. Charles River Laboratories International has a 12 month low of $139.76 and a 12 month high of $343.47.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Tuesday, May 4th. The medical research company reported $2.53 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.19 by $0.34. Charles River Laboratories International had a return on equity of 22.41% and a net margin of 10.68%. The firm had revenue of $824.60 million for the quarter, compared to analysts’ expectations of $798.52 million. During the same quarter in the previous year, the company earned $1.84 earnings per share. The firm’s quarterly revenue was up 16.6% compared to the same quarter last year. Equities research analysts anticipate that Charles River Laboratories International will post 7.87 EPS for the current year.

Several equities analysts have weighed in on CRL shares. Credit Suisse Group lifted their price objective on shares of Charles River Laboratories International from $259.00 to $301.00 and gave the stock a neutral rating in a research report on Thursday, February 18th. Truist boosted their price objective on shares of Charles River Laboratories International from $256.00 to $324.00 in a report on Thursday, February 18th. Zacks Investment Research downgraded shares of Charles River Laboratories International from a buy rating to a hold rating in a report on Monday, April 19th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Charles River Laboratories International from $250.00 to $334.00 and gave the company a buy rating in a research note on Thursday, February 25th. Finally, Morgan Stanley upped their target price on shares of Charles River Laboratories International from $280.00 to $350.00 and gave the company an overweight rating in a research note on Thursday, February 25th. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $260.80.

In other Charles River Laboratories International news, VP Birgit Girshick sold 1,675 shares of the stock in a transaction on Friday, February 19th. The shares were sold at an average price of $293.92, for a total value of $492,316.00. Following the completion of the sale, the vice president now owns 31,680 shares in the company, valued at $9,311,385.60. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO David Ross Smith sold 3,845 shares of the firm’s stock in a transaction dated Thursday, April 22nd. The stock was sold at an average price of $330.00, for a total transaction of $1,268,850.00. Following the sale, the chief financial officer now owns 18,707 shares of the company’s stock, valued at approximately $6,173,310. The disclosure for this sale can be found here. In the last quarter, insiders sold 111,363 shares of company stock valued at $32,201,105. Corporate insiders own 1.90% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Further Reading: What is the Moving Average Convergence Divergence (MACD) oscillator?

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.